Jaber Ibn Hayyan Pharmaceutical

What Jaber Ibn Hayyan Pharmaceutical does

Jaber Ibn Hayyan Pharmaceutical Company (شرکت داروسازی جابرابن حیان) is an Iranian manufacturer of generic pharmaceutical products, headquartered in Tehran and listed on the Tehran Stock Exchange under the ticker symbol Djaber (دجابر). Operating history extends back to 1960, when the company was established as Squibb Iran under a US Squibb license, was nationalized under the National Industries Organization following the 1979 Islamic Revolution, and was converted into a public joint stock company (سهامی عام) in 1991. The company carries ISO 9001:2018, ISO 14001:2018, ISO 45001:2018, ISO 1002:2018, and ISO 17025:2017 certifications and operates with 501-1,000 employees.

The product portfolio spans eight dosage-form categories: metered-dose inhalers, nasal sprays, sterile injectable vials (penicillins, cephalosporins including ceftazidime-avibactam, carbapenems, glycopeptides, and adjunctive injectables), topical ointments, soft gelatin capsules (both supplements and prescription molecules), oral and vaginal tablets, oral capsules, and pediatric oral suspensions. Coverage spans antibiotics, respiratory, cardiovascular, CNS, gastrointestinal, anti-allergy, endocrine, dermatology, antifungal, antiviral, and nutritional supplement therapeutic areas. Core technical capability is concentrated in sterile injectable manufacturing and respiratory inhalation/nasal spray dose-metering systems.

The company generates revenue through wholesale and retail distribution of generic pharmaceuticals to hospitals, pharmacies, and healthcare providers across Iran. Its principal distribution partner is Shafa Pharmaceutical Distribution Company, which provides nationwide hospital and pharmacy channel coverage, complemented by direct supply to large accounts. Reported commercial momentum includes 459 billion Tomans in two-month sales and a record monthly sales figure in Azar 1404 (December 2025). Pricing is subject to oversight by the Food and Drug Organization of Iran, and pricing details are not publicly disclosed. Geographic footprint is principally domestic with claimed Middle East market presence; no material export revenue data is disclosed.

Name

Jaber Ibn Hayyan Pharmaceutical

Legal name

Jaber Ibn Hayyan Pharmaceutical Company (شرکت داروسازی جابر ابن حیان)

Website

https://jaber-pharma.com

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

101–250 employees

Short description

Jaber Ibn Hayyan Pharmaceutical is a publicly listed Iranian manufacturer of generic pharmaceuticals, headquartered in Tehran and trading on the Tehran Stock Exchange as Djaber. Founded in 1960 and operating with 501-1,000 employees, it produces injectable antibiotics, respiratory and nasal sprays, topical ointments, tablets, soft gelatin capsules, and oral suspensions for hospitals, pharmacies, and patients across Iran.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceutical manufacturing
• Injectable antibiotic production
• Respiratory inhalation products
• Nasal spray medications
• Topical dermatological formulations

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: The company manufactures and sells a broad portfolio of generic pharmaceutical products including injectable antibiotics, respiratory sprays, nasal sprays, topical medications, soft gelatin capsules, tablets, capsules, and oral suspensions. Revenue is generated through wholesale and retail distribution channels within Iran's pharmaceutical market. Two-month sales reported at 459 billion Tomans with record-breaking monthly sales achieved in Azar 1404.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Jaber Ibn Hayyan Pharmaceutical manufactures and sells a diversified portfolio of generic pharmaceutical products in Iran and the broader Middle East. Its offering centers on injectable antibiotics (penicillins, cephalosporins, carbapenems, glycopeptides), metered-dose inhalers and nasal sprays for respiratory and allergic conditions, topical ointments, soft gelatin capsules, oral tablets, capsules, and pediatric oral suspensions covering therapeutic areas such as anti-infectives, cardiovascular, CNS, gastrointestinal, endocrine, and dermatology. Products are supplied under the company's own brand via pharmaceutical distribution partners to hospitals, pharmacies, and ultimately patients.

Product overview

Jaber Ibn Hayyan Pharmaceutical Company is a diversified pharmaceutical manufacturer with over 60 years of experience, specializing in injectable and non-injectable antibiotics and respiratory sprays. The company's product portfolio encompasses eight main categories: (1) Metered-dose inhalers (Salbutrex 100, Ipratrex-S, Ipratrex, Beclotrox 50, Budesonide, Flutizox, Flusalmex, Budoformex) for respiratory conditions; (2) Nasal sprays (Desmonix, Azelastine, Patanix, Caltonix, Oxynix, Ephonix, Beclometasone, Budenix) for allergic rhinitis and nasal congestion; (3) Injection vials including penicillins (Ampicillin, Cloxacillin, Penicillin G 6-3-3, Penicillin G Benzathine, Penicillin G Procaine), cephalosporins (Cefemax/Cefepime, Zoxime/Ceftizoxime, Cephotax/Cefotaxime), and other antibiotics; (4) Topical ointments (Nistat, Calcipotriol, Triamcicort, Triamcicort NN, Momenix, Hydrocortisone, Clobetazole); (5) Soft gelatin capsules including supplements (Evening Primrose Oil, Vitamin E, Omega-3, Simethicone, Castor Oil) and medications (Tempraphen/Acetaminophen, Gelopain/Ibuprofen, Tempraphen-C/Acetaminophen-Codeine, Soft Cold); (6) Oral and vaginal tablets (Rivaroxaban, Escitalopram, Sertraline, Sitagliptin, Sitagliptin-Metformin, Fexofenadine, Cefixan, Clotizol, Nistatin); (7) Oral capsules (Kephalex/Cephalexin, Amoxcill/Amoxicillin); (8) Oral suspensions for pediatric use. The company is recognized as a major producer of injectable and non-injectable antibiotics in Iran and the Middle East.

Differentiator

Problem solved

Functional benefit

Products and services

• Metered-Dose Inhalers (Respiratory Line) Range of pressurized metered-dose inhalers containing salbutamol, ipratropium, beclomethasone, budesonide, fluticasone, salmeterol, and formoterol, for asthma, COPD, and bronchodilation. Intended for prescription use by physicians and dispensing through pharmacies and hospitals.
• PHR160 Oral Inhalable Spray Oral inhalable spray developed and launched in 2020 during the COVID-19 pandemic to support early-phase COVID-19 patients by helping maintain blood oxygen levels and reducing pulmonary complications. Manufactured under official authorization from the Iranian Ministry of Health.
• Nasal Spray Line (Allergic Rhinitis and Decongestants) Nasal spray products including Desmonix (desloratadine), Azelastine, Patanix (azelastine/fluticasone), Caltonix (calcitonin), Oxynix (oxymetazoline), Ephonix (phenylephrine), Beclometasone, and Budenix (budesonide) for allergic rhinitis, congestion, and related nasal conditions. Distributed through pharmacies for patient and physician use.
• Sterile Injectable Antibiotics (Penicillins and Cephalosporins) Sterile powder-for-injection antibiotic vials including Ampixill (ampicillin), Cloxacillin, Penicillin G 6-3-3, Penicillin G Benzathine (Pen LA), Penicillin G Procaine, Cefemax (cefepime), Zoxime (ceftizoxime), and Cephotax (cefotaxime). Indicated for severe bacterial infections, meningitis, pneumonia, UTIs, gonorrhea, and rheumatic fever prevention. Sold primarily to hospitals and clinical settings.
• Topical Ointments (Dermatology Line) Topical dermatological ointments including Nistat (antifungal), Calcipotriol (psoriasis), Triamcicort and Triamcicort NN (triamcinolone), Momenix (mometasone), Hydrocortisone, and Clobetazole for fungal infections, psoriasis, and inflammatory skin conditions. Sold through pharmacies on prescription.
• Soft Gelatin Capsules (OTC and Supplement Line) Soft gelatin capsule products covering Evening Primrose Oil and Vitamin E (supplements), Simethicone (antiflatulent), Castopearl castor oil (laxative), Tempraphen (acetaminophen), Gelopain ibuprofen liquigel, Tempraphen-C (acetaminophen/codeine), and Soft Cold day/night cold and flu formulations. Distributed to pharmacies for OTC and prescription use.
• Oral Solid Tablets (Cardiovascular, CNS, Antidiabetic, Antihistamine) Oral solid tablets including Rivaroxaban (anticoagulant), Escitalopram and Sertraline (SSRIs), Sitagliptin and Sitagliptin-Metformin (antidiabetics), Nistatin (antifungal), Fexofenadine (antihistamine), and Cefixan cefixime (oral cephalosporin). Indicated for outpatient and inpatient treatment of cardiovascular, psychiatric, metabolic, allergic, and infectious conditions.
• Clotizol (Clotrimazole) Vaginal Tablet Antifungal vaginal tablet containing clotrimazole for treatment of vaginal candidiasis. Sold through pharmacies on prescription.
• Oral Antibiotic Capsules Oral antibiotic capsules including Kephalex (cephalexin) first-generation cephalosporin and Amoxcill (amoxicillin) penicillin antibiotic for respiratory, skin, and other bacterial infections. Distributed to pharmacies for outpatient use.
• Pediatric Oral Suspensions Oral suspension powder products for reconstitution including Nistat (antifungal), Cefixan (cefixime), Amoxcill (amoxicillin), Coamoxiclav (amoxicillin-clavulanic acid), and Kephalex (cephalexin) for pediatric bacterial and fungal infections. Sold through pharmacies.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Shafa Pharmaceutical Distribution Company (شرکت پخش رازی)coreChannel Partner/ Reseller/ DistributorShafa Pharmaceutical Distribution Company (Razi Co.) is a major pharmaceutical distribution partner that distributes Jaber Ibn Hayyan's pharmaceutical products throughout Iran's healthcare network to hospitals, pharmacies, and other healthcare providers.
• Shafa Darou Investment Company (شرکت سرمایه گذاری شفا دارو)coreStrategic or Co-development PartnerShafa Darou Investment Company is a pharmaceutical investment company listed as a key partner and collaborator of Jaber Ibn Hayyan Pharmaceutical, representing part of the company's strategic business network.
• Food and Drug Organization of Iran (سازمان غذا و دارو)coreOthersThe Food and Drug Organization (FDA) of Iran's Ministry of Health and Medical Education is the regulatory body overseeing pharmaceutical manufacturing, licensing, and market authorization for all pharmaceutical products in Iran, including those manufactured by Jaber Ibn Hayyan.
• Ministry of Health and Medical Education of Iran (وزارت بهداشت و درمان)coreOthersThe Iranian Ministry of Health and Medical Education is the governing body for all health-related activities including pharmaceutical manufacturing regulation, GMP compliance, and healthcare policy implementation in Iran.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered multinational generic pharmaceutical manufacturer with strong MENA presence, producing injectables, antibiotics, and respiratory products. Comparable as a broader incumbent generic pharma player in the Middle East with overlapping product categories and regional market positioning.
• Cipla: Indian-headquartered global generic pharmaceutical giant with major respiratory and anti-infective franchises. Comparable as a broad incumbent in generic pharmaceuticals, particularly respiratory/inhalation products and antibiotics, that could expand into the Middle East market where Jaber operates.

Direct peers

• Actoverco Pharmaceutical Company: Iranian pharmaceutical manufacturer specializing in solid dosage forms, injectables, and specialty pharmaceuticals. Comparable through shared focus on generic drug manufacturing for the Iranian healthcare system with similar regulatory and distribution dynamics.
• TPICO (Tehran Pharmaceutical Investment Company): Tehran-based pharmaceutical holding and manufacturer producing generic medicines across multiple dosage forms. Comparable as a publicly-listed Iranian pharma peer with overlapping horizontal product portfolio and similar distribution model.
• Barakat Pharmaceutical Company: Iranian pharmaceutical manufacturer with diversified portfolio across multiple therapeutic categories including injectables and respiratory products. Direct peer operating in the same domestic generic pharma market with similar channel structure.
• Zahravi Pharmaceutical Company: Iranian pharmaceutical manufacturer producing generic injectables, antibiotics, and specialty products for domestic and regional markets. Direct peer through overlapping injectable antibiotic portfolio and domestic distribution channels.
• Sobhan Oncology Pharmaceutical Company: Iranian specialty pharmaceutical manufacturer focused on oncology and injectable products. Comparable through sterile injectable manufacturing capabilities and shared Iranian institutional customer base (hospitals, specialty clinics).
• Loghman Pharmaceutical & Hygienic Company: Iranian pharmaceutical manufacturer with broad portfolio including antibiotics, respiratory, and topical products. Direct peer given overlapping therapeutic categories and shared Iranian distribution network through Shafa and similar partners.
• Tofigh Daru Pharmaceutical Company: Iranian pharmaceutical manufacturer focused on antibiotics, injectables, and sterile products with publicly listed status. Highly comparable given overlapping product categories (injectable antibiotics, sterile manufacturing) and similar Tehran Stock Exchange listing structure.
• Darou Pakhsh Pharmaceutical Company: Iran's largest pharmaceutical manufacturer, producing a broad range of generic drugs, injectables, and specialty pharmaceuticals. Directly comparable as a major domestic generic pharma competitor serving the same Iranian hospital and pharmacy channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jaber Ibn Hayyan Pharmaceutical